US 10251874
Crystalline forms of a JAK inhibitor compound
granted A61KA61K31/4468A61K9/0075
Quick answer
US patent 10251874 (Crystalline forms of a JAK inhibitor compound) held by Theravance Biopharma R&D IP, LLC expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K31/4468, A61K9/0075, A61P, A61P11/00